drugset / Trial / NCT01250730

A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

NCT01250730

Phase 1 Completed 18 enrolled Pfizer
Parallel-groupOpen-label

Summary

The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.

Timeline

Start
2010-12
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Crizotinib Small molecule 150 mg
Subject Crizotinib Small molecule 250 mg
Subject Crizotinib Small molecule 400 mg

Indications

No indication recorded.